| Assessment Status | Rapid Review Complete |
| HTA ID | 25070 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) is indicated in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with human epidermal growth factor (HER2)-negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours express programmed death-ligand 1 (PD-L1) with a tumour area positivity (TAP) score ≥ 5. |
| Assessment Process | |
| Rapid review commissioned | 11/12/2025 |
| Rapid review completed | 18/12/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.